Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPSO 1005
- Development stage
- Unknown
- Lead developer
- Sound
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SPSO 1005 is an investigational drug candidate being developed by Spriaso LLC for the treatment of central nervous system (CNS) disorders. The agent is currently in the early clinical development stage, having transitioned from pre-clinical research. Spriaso specializes in the development of proprietary delivery platforms intended to improve patient compliance and therapeutic outcomes, often by optimizing the delivery of established drug classes. While SPSO 1005 has undergone proof-of-principle studies, specific details regarding its molecular target, mechanism of action, and the specific CNS indication it targets remain proprietary and have not been publicly disclosed.
02
Targets
GPX1 (Glutathione peroxidase 1)
Beyond the preview
Go deeper on SPSO 1005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPSO 1005.